Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer ...

Analyst Puneet Souda of Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), reducing the price target ...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) ...

Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $22.1 million in its third quarter. On a per-share basis, the Salt Lake City-based company said ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

The industry is now watching to see how this development will shape the company's financial outlook and whether other insurers will follow UNH's lead. In other recent news, Myriad Genetics has ...

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine, announced its disagreement with UnitedHealthcare's recent policy ...

周一，TD Cowen维持Myriad Genetics (NASDAQ:MYGN)股票的持有评级，目标价保持在$30.00不变。这一决定是在联合健康(UNH)最近更改药物基因检测政策之后做出的。 具体而言，UNH更新了其指南，排除了对多基因检测的覆盖，包括Myriad Genetics的GeneSight产品，该产品用于指导抗抑郁药物治疗。在这一公告之后，Myriad Genetics的股价下跌 ...

(Bloomberg) -- Donald Trump is planning to ask a New York judge to throw out his hush-money conviction in the wake of his ...

The market's response to the news has been notably negative, but it remains to be seen whether the current drop in Myriad Genetics' stock price is an overreaction or an accurate reflection of the ...